滚动资讯
Novo NordiskA proposal seeks to remove Novo and Lilly drugs from key list in the US – will provide better protection against copies - medwatch.comFierceBiotech安进因临床2期数据不佳，放弃癌症及干燥综合征候选药物AmgenAmgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce BiotechSamsung Biologics(LEAD) Samsung Biologics union launches 1st general strike over pay dispute - Yonhap News AgencySamsung BiologicsSamsung Biologics, Lilly to Launch Biotech Hub Supporting Venture Ecosystem - Seoul Economic DailyBioPharma Dive两家生物科技公司在最新一轮IPO中总共筹集5.56亿美元Merck & Co.聚焦：默克公司维持业务拓展兴趣，瞄准700亿美元销售目标 - FirstWord PharmaSiemens Healthineers西门子医疗面临重大转折：诊断业务出售、分拆延迟，股价跌至谷底 - 突发新闻Samsung BiologicsSamsung Biologics union launches 1st general strike over pay dispute - The Korea TimesThermo Fisher投资者对赛默飞世尔科学公司(TMO)扩建美国生物工艺设计中心的反应Novo NordiskNovo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO - Bloomberg.comBio-RadBio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
Endpoints News 2026年3月16日

BioMarin因安全问题暂停部分患者Voxzogo二期试验用药。

BioMarin因安全问题暂停部分患者Voxzogo二期试验用药。

原文
暂时没有全文，请查看原始来源。